Nivolumab for Gastric Cancer: 17 Real Stories

Gastric cancer treatment during hemodialysis after liver recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver|peritoneum

The cancer progressed in the peritoneum despite treatment, and systemic therapy was stopped in August 2024 before transfer to hospice in October 2024.

PubMed CentralRead more →

Gastric cancer surgery and adjuvant treatment followed by endocrine complications

Patient Info: Anonymized, Female, 40s

After cancer treatment, she was hospitalized with severe nutritional and endocrine complications and improved with hormone replacement and nutritional support.

PubMed CentralRead more →

Complete response in Stage IV gastric cancer after chemotherapy, immunotherapy, and surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative; MSS; PD-L1 high

Metastatic Site: liver

He achieved a complete pathologic response and remained free of recurrence for 3 years and 3 months after surgery.

PubMed CentralRead more →

Stage IV gastric cancer with benign breast hemangioma during ramucirumab therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Gastric cancer: HER2 negative, PD-L1 TPS >=5%

Metastatic Site: peritoneum; preaortic lymph nodes; omentum

After initial response to FOLFOX/nivolumab and temporary benefit from paclitaxel/ramucirumab and FOLFIRI, the gastric cancer progressed to massive ascites. Trifluridine/tipiracil was attempted, but she died from rapid disease progression.

PubMed CentralRead more →

Metastatic Gastric Cancer Treatment Complicated by Recurrent Cytokine Release Syndrome

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: peritoneum, bone

She had a partial response after 6 cycles but later chose to stop chemotherapy because treatment toxicity and declining health were affecting quality of life.

PubMed CentralRead more →

Stage IV Gastric Cancer Responds to Nivolumab Before Severe Immune Hepatitis

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: HER2 1+; PD-L1 tumor-cell score 5%; mismatch-repair proteins intact; p53 mutated

Metastatic Site: liver

After an initial reduction in the gastric tumor and liver metastases, nivolumab was stopped for severe hepatitis and later disease progression with multi-organ failure was documented.

PubMed CentralRead more →

Metastatic gastric cancer with an ATM mutation responding to olaparib

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: Pathogenic germline ATM mutation, HER2-negative, PD-L1 15%

Metastatic Site: peritoneum

He had a deep response lasting about 18 months, but imaging in December 2023 again showed peritoneal carcinomatosis.

PubMed CentralRead more →

Stage IV gastric cancer with liver metastases cleared after chemotherapy, nivolumab and surgery

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1-positive, HER2-negative

Metastatic Site: liver

After treatment cleared the gastric and liver lesions, all anticancer therapy was stopped. He remained relapse-free with no evidence of disease for 32 months.

PubMed CentralRead more →

Stage IV gastric cancer with a TP53 blood finding traced to clonal hematopoiesis

Patient Info: Anonymized, male, 50s | Stage IV

Metastatic Site: distant lymph nodes

At age 57, 3 years 4 months after his Stage IV diagnosis, he remained alive after multiple lines of treatment; progression had occurred before his later-line regimens.

PubMed CentralRead more →

Long-term complete response to nivolumab after recurrent Stage IV gastric cancer

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: HER2-negative, PD-L1 CPS ≤1

Metastatic Site: peritoneum, distant lymph nodes

About 7 years after surgery and roughly 3 years after starting nivolumab, CT showed no recurrent nodules or enlarged lymph nodes. She remained on nivolumab with a complete clinical response, had regained weight and returned to work.

PubMed CentralRead more →

Kidney Injury During Nivolumab Treatment for Stage IV Gastric Cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Kidney function and proteinuria improved after nivolumab was stopped, but the gastric cancer progressed. Restarted nivolumab was ineffective, and treatment was changed to irinotecan.

PubMed CentralRead more →

Sjögren syndrome during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, lungs, adrenal gland

One year after nivolumab was stopped, the shrinkage of lung metastases was maintained and the adrenal metastasis remained unchanged, although severe dry-mouth symptoms from treatment-related Sjögren syndrome persisted.

PubMed CentralRead more →

MSI-High Gastric Cancer With a Complete Response to Preoperative Nivolumab

Patient Info: Anonymized, Female, 60s

Biomarkers: MSI-high; PD-L1 expression in more than 1% of tumor cells; HER2 negative

Surgery found a complete pathologic response with no residual tumor cells and no cancer in 12 lymph nodes. At the time of reporting, she had no complaints and had returned to normal activities.

PubMed CentralRead more →

Graves disease during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, brain

After progression through several treatment lines and development of brain metastasis, he died 4 months after evaluation for nivolumab-associated Graves disease, more than 1.5 years after his Stage IV gastric-cancer diagnosis.

PubMed CentralRead more →

Nivolumab-related IgA kidney disease during treatment for Stage IV gastric cancer

Patient Info: Anonymized, male, 70+ | Stage IV

The gastric tumor regrew while nivolumab was withheld. Kidney function improved with steroids, but recurrent pneumonia and poor performance status prevented immunotherapy from restarting.

PubMed CentralRead more →

Clival skull-base metastasis during treatment for Stage IV gastric cancer

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: HER2-negative

Metastatic Site: peritoneum, cervical lymph nodes, pelvic bone, lungs,…

At publication he was alive on fourth-line treatment, with no disease progression for 6 months after the clival metastasis was treated and with sustained improvement in his cranial-nerve symptoms.

PubMed CentralRead more →

Stage IV gastric cancer complicated by paraneoplastic dermatomyositis during nivolumab treatment

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: liver, lung, abdominal cavity

He died from rapidly worsening gastric cancer 142 days after the first nivolumab dose, roughly 14 months after his April 2017 diagnosis.

PubMed CentralRead more →